Carbon Monoxide and Nitric Oxide Induced-Heme-Based Modification of Alpha-2-Antiplasmin and Plasmin Activity by Arkebauer, Matthew R.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Biomedical Studies Student Scholarship Student Dissertations, Theses and Papers
2011
Carbon Monoxide and Nitric Oxide Induced-
Heme-Based Modification of Alpha-2-Antiplasmin
and Plasmin Activity
Matthew R. Arkebauer
Philadelphia College of Osteopathic Medicine, matthewar@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/biomed
Part of the Biochemistry Commons, and the Medicine and Health Sciences Commons
This Thesis is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been
accepted for inclusion in PCOM Biomedical Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more
information, please contact library@pcom.edu.
Recommended Citation
Arkebauer, Matthew R., "Carbon Monoxide and Nitric Oxide Induced-Heme-Based Modification of Alpha-2-Antiplasmin and
Plasmin Activity" (2011). PCOM Biomedical Studies Student Scholarship. Paper 3.
  
 
 
 
 
 
   
 
 
 
 
  
 
  
 
The Philadelphia College of Osteopathic Medicine
Master of Biomedical Sciences Program
Hahnemann University Hospital 

Department of Anesthesiology
 
CARBON MONOXIDE AND NITRIC OXIDE INDUCED-HEME-BASED 

MODIFICATION OF ALPHA-2-ANTIPLASMIN AND PLASMIN ACTIVITY
 
A Thesis in Biomedical Sciences by Matthew Robert Arkebauer
 
Submitted in Partial Fulfillment of the Requirements for the Degree of

Master of Biomedical Sciences
 
July 2011
 
  
                        
 
                      
 
 
 
 
 
_______________________________  _____________ 
  
 
  
 
 
_______________________________  _____________ 
 
  
 
  
 
_______________________________  _____________ 
 
 
  
 
 
Signatory Page
We approve the thesis of Matthew Robert Arkebauer
Vance G. Nielsen, M.D.                          Date of Signature
Professor of Anesthesiology, Director of Research
Hahnemann University Hospital
Thesis Advisor
Ruth D. Thornton, Ph.D.  Date of Signature
Professor & Chair, Department of Biochemistry/Molecular Biology
Philadelphia College of Osteopathic Medicine
Committee Advisor
S. Nini Malayaman, M.D.  Date of Signature
Instructor of Anesthesiology, Assistant Director of Research
Hahnemann University Hospital
Thesis Committee Member
  
 
  
 
 
  
 
 
    
 
    
    
    
  
 
 
 
 
  
 
Abstract
CARBON MONOXIDE INDUCED/HEME-BASED MODIFICATION OF
 
ALPHA-2-ANTIPLASMIN AND PLASMIN ACTIVITY
 
Matthew R. Arkebauer
 
Master’s of Biomedical Sciences, June 2011
Philadelphia College of Osteopathic Medicine
 
Vance G. Nielsen, M.D., Thesis Adviser
 
Objectives: Carbon monoxide (CO) derived from cigarette smoke or released 
from carbon monoxide releasing-molecule 2 (CORM-2), diminishes fibrinolysis.  
The primary purpose of this study was to determine if CO diminished fibrinolysis
by means of enhancing α2-antiplasmin via an alleged heme group.
Methods: Plasma, isolated α2-antiplasmin and isolated plasmin were exposed
to CO released from CORM-2 (tricarbonyldichlororuthenium (II) dimer) and
nitric oxide (NO) via a NO donor to induce carboxyheme and metheme states.  
Exposed, isolated enzymes were placed in either α2-antiplasmin deficient or
normal plasma.  Effects of CO and NO on tissue-type plasminogen activator
initiated fibrinolysis were determined by thrombelastography.  Liquid 
chromatography-mass spectrometry (LC-MS/MS, see Table 1) was used to 
identify heme released from α2-antiplasmin and plasmin.
Results: CO significantly enhanced α2-antiplasmin activity but decreased 
plasmin activity.  NO decreased both α2-antiplasmin and plasmin activity.  While
i
   
 
 
 
  
 
   
insufficient LC-MS/MS data was obtained with α2-antiplasmin (secondary to 
glycosylation), a putative plasmin-associated heme was identified.
Conclusion:  CO causes hypofibrinolysis by enhancing α2-antiplasmin 
activity and decreasing plasmin activity.  Based on responses to NO and LC­
MS/MS data, it is highly likely that both enzymes are modulated by attached 
heme groups.  Attempts to develop methods to detect CO-mediated 
hypercoagulability are ongoing, with the goal of identifying populations at risk of 
thrombotic morbidity secondary to cigarette smoking.
ii
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Chapter 1: Introduction
The health problems associated with cigarette smoking have been thoroughly
researched and are well known.  Cigarette smoking afflicts nearly every organ in 
the human body and decreases the overall general health of smokers (1).  Adverse
health effects of cigarette smoking account for an estimated 443,000 deaths, or
nearly 1 in 5 deaths in the U.S. each year (2, 3).  The yearly death count caused by
tobacco use is more than all deaths from human immunodeficiency virus (HIV), 
illegal drug use, alcohol use, motor vehicles injuries, suicides and murders 
combined (3). A smoker’s risk factors are increased 2 to 4 times for coronary
heart disease and stroke, 23 times for men in developing lung cancer, 13 times for
women in developing lung cancer and 12 to 13 times for dying from chronic
obstructive lung diseases compared with nonsmokers (1).  
In the U.S., cigarettes are regulated to 599 additives, carbon monoxide (CO)
being an important poisonous component of tobacco smoke (4). Carbon monoxide 
inhalation while smoking results in increased levels of carboxyhemoglobin
(COHb, see Table 1), causing decreased oxygen delivery to cells (5-7). This 
occurs because carbon monoxide competes with oxygen (O2) in binding with 
hemoglobin.  Excess quantities of CO impair oxygen delivery to cells because 
hemoglobin preferentially binds CO compared to O2 at a ratio of approximately
240:1 (8). Tobacco smoke inhalation has been linked to numerous diseases, an 
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important one being thrombotic disease (9-11).  Studies have demonstrated that 
CO influences the hemostatic system causing increased coagulation and decreased
fibrinolysis (see Table 1) (12-21).  Tobacco smoke, which contains CO, can be
considered a significant risk factor for the pathogenesis of thrombotic diseases (9­
11).   
Normal hemostasis is a phenomenon caused by a tightly controlled process to 
(i) maintain blood in a fluid state in normal vessels, (ii) provide a means of
rapidly forming a hemostatic clot at a site of vascular injury, and then (iii) restore
normal flow through fibrinolytic processes (22, figure 1).  Thrombosis is the 
formation of a blood clot in intact vessels, involving three components: reactions 
at the vascular wall, the actions of platelets, and the coagulation cascade (22).  
At a site of vascular injury, the vascular wall vasoconstricts, primarily due to 
the molecule endothelin.  Next platelets are activated and adhere to the site of
vascular injury.  Platelets aggregate together to form a hemostatic plug at the site
of injury.  This process is known as primary hemostasis.  Circulating Tissue
Factor (TF, see Table 1) is exposed to the site of injury and along with FVII, is 
the primary initiator of the coagulation cascade.  A chain-reaction occurs of
various factors activating the next one sequentially until thrombin (see Table 1) is 
generated and cleaves fibrinogen to produce the insoluble fibrin (see Table 1)
(22).  A fibrin meshwork is created which recruits more platelets and induces 
cross-linking via FXIII to create a stronger plug.  The production of this fibrin 
meshwork plug is known as secondary hemostasis, eventually forming a more
permanent plug (22).  This more permanent plug prevents further hemorrhage at 
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the site of vascular injury.  To restore the balance of hemostasis, vascular repair
occurs and tissue plasminogen activator (tPA, see Table 1) activates plasmin (see
Table 1), the primary enzyme of fibrinolysis.  Plasmin cleaves the fibrin 
meshwork thus breaking down the more permanent plug.  An important 
fibrinolytic regulatory enzyme which inhibits the activity of plasmin is α2­
antiplasmin (see Table 1).  For a detailed explanation of the sequential events of 
the coagulation cascade as well as the counter-regulatory actions of the
fibrinolytic cascade see figure 1.
While the mechanisms and sequential effects of the coagulation cascade are
well established, the complete structural and mechanistic biochemistry of the 
many molecules participating in the coagulation cascade remain to be discovered.
Previous studies by Dr. Vance Nielsen’s research group used the carbon 
monoxide releasing molecule-2 (CORM-2; tricarbonyldichlororuthenium (II)
dimer, Figure 2) to deliver CO to plasma-based systems and study the effect of 
CO on coagulation and fibrinolysis (12-21).  The degradation of heme (see Table 
1) by heme oxygenase produces CO, as does cigarette smoking.  Carbon 
monoxide can also be produced pharmacologically by carbon monoxide releasing
molecules (CORMs).  Studies have established that CORMs have the ability to 
cause vasodilation, decrease inflammation, ease ischemia-reperfusion injury,
diminish apoptosis and prevent arterial thrombosis (12, 23-27). CORMs are metal 
carbonyls containing CO bound to a variety of heavy metals such as iron, cobalt, 
nickel and ruthenium (25, 26).  The release of CO from these metals can be
modulated by photoactivation, temperature, pH and the nature of the ambient 
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environment (e.g. organic solvent or physiological aqueous solution) (25, 26).   
The CO released from CORMs has been viewed as a modulator or cell signaling
molecule, comparable to nitric oxide (NO) in its effects of the above mentioned 
circumstances (23-27).  
Dr. Nielsen discovered that CO was found to enhance the speed of clot growth 
and final clot strength via the modification of fibrinogen, the substrate of
thrombin.  He found that CO also decreased tPA-induced fibrinolysis (13). 
Diminished fibrinolysis was found to be accomplished by CO increasing the
effect of the antifibrinolytic serine protease inhibitor; α2-antiplasmin (Figure 3), 
suggesting that the effect of CO on fibrinolysis is α2-antiplasmin-dependent (13, 
18, 28). 
Similar results through independent studies have used blood obtained from 
smokers, documented via thrombelastography (see Table 1).  These studies 
showed enhanced clot strength, antifibrinolytic responses to tPA-mediated lysis, 
and denser matrix of thin fibrin polymers (13, 29). These studies led to the
conclusion that CO affects the coagulation cascade by causing faster-growing, 
stronger thrombus clots which take longer to lyse, and result in a hypercoagulable
state.
The optimal determined concentration of CO used in these studies was 75μM, 
which in turn is expected to raise whole blood COHb concentration <0.5% (12­
21).  This is rather significant data, since smokers using a half-pack to two-pack 
per day have COHb concentrations of 3-7% (5), compared to smoke inhalation 
victims with CO concentrations around 7-20% (1000-3000μM) (30).  These
4
 
   
  
 
   
   
  
 
   
   
  
   
  
   
   
  
  
   
 
studies indicate that chronic smokers and smoke inhalation victims are exposed to 
CO concentrations significantly higher than those studied and shown to cause
increased coagulation and decreased fibrinolysis (5-7, 12-21, 30, 31).  This may
strengthen the theory of a hypercoagulable/hypofibrinolytic state associated with 
smoking.
There are many scenarios in which the hypercoagulable/hypofibrinolytic
effects of CO released by CORMs may potentially be utilized both clinically and 
therapeutically.  In preclinical rat and rabbit plasma, CORM-2 has been shown to 
display procoagulant and antifibrinolytic effects, with response in rabbit plasma
being most similar to that of humans (32). CORM-2 also has the same 
procoagulant/antifibrinolytic effects in the plasma of chronically anticoagulated 
patients on Warfarin (see Table 1), thus indicating a possible therapeutic
treatment for bleeding patients at risk for thrombosis if their anticoagulation was 
reversed significantly with blood products or Recombinant Activated Factor VII
(see Table 1) (i.e. mechanical heart valve or left ventricular device) (17). CORM­
2 shows promise in hemophiliac human plasma as well as human plasma diluted 
with resuscitative fluids (i.e. trauma-associated bleeding) (14, 19). There are also 
studies showing the efficacy of CORM-2 as a procoagulant/antifibrinolytic in 
plasma exposed to heparin or Argatroban (see Table 1), hypothermic conditions, 
and in the attenuation of Protamine-mediated hypocoagulation/hyperfibrinolysis
(see Table 1) (20).
While the effects of CORM-2-released CO on human plasma are known to 
induce coagulation and attenuate fibrinolysis, the exact mechanism of action is
5
 
   
    
  
    
 
  
    
   
 
   
  
   
 
  
 
 
 
   
  
unknown. An insight into the structural changes of fibrinogen caused by CORM-
2-released CO occurred when it was discovered that CO causes a decrease in
thick diameter fiber formation and an increase in the production of “stronger” thin 
diameter fibrin fibers (15). Interestingly a separate and unrelated study using
thrombelastography and electron microscopy to study whole blood of smokers 
revealed similar results; smokers’ blood had increased clot strength and produced 
significantly denser thin fibrin clot fibers than nonsmokers’ blood (33). However, 
the mechanism by which CO directly modifies fibrinogen was still undetermined.
An investigation into CO modification of fibrinogen was then completed
using liquid-chromatography-mass spectroscopy (LC-MS). Previous studies 
examined the modification of enzymatic function, using the mechanism of O2, 
NO, or CO binding to a heme molecule attached to a protein of interest.  From 
these studies, it was proposed that a heme group could be associated with 
fibrinogen.  LC-MS found no direct modifications of the amino acids in 
fibrinogen, but small portions of both the α and γ chains could not be detected 
following exposure to CORM-2 and endoproteinase digestions with trypsin and 
Glu-C.  Interestingly, an ion with the same mass-to-charge ratio (m/z) and 
retention time as heme was found in purified fibrinogen.  Heme has a molecular
weight of 616.18 in the reduced Fe
2+ 
state.  During mass spectrometry, heme 
binding proteins are known to liberate free heme which can be detected at m/z
617.18 in the
+1 
charge state.  The molecular ion identified by mass spectrometry
of a purified fibrinogen sample had an m/z of 617.18 identical to that of heme.
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In addition, exposure of plasma to NO by a NO-donating molecule (sodium 
nitroprusside) and a heme oxidizing agent (hydroquinone) together decreased 
CORM-2 mediated enhancement of coagulation, as compared to the coagulation 
kinetics of plasma not exposed to CORM-2.  The combination of sodium 
nitroprusside and hydroquinone decreased CORM-2 mediated increases in the
speed of clot growth (by 40%) and strength (by 50%).  
The result of these preliminary two studies was that CO derived from CORM­
2 likely modifies fibrinogen via modulation of a heme group(s) associated with 
fibrinogen.  Hence the conclusion of these studies is that fibrinogen is a CO-
sensing molecule (34).
The proposed mechanism was discovered in which CORM-2 modulates
fibrinogen with respect to CO-mediated hypercoagulation, thus describing half of
the observed effects of CORM-2 on hemostasis.  Fibrinogen affects coagulation, 
and CO-modulated fibrinogen forms a faster growing and stronger clot.  
However, fibrinogen per se doesn’t necessarily increase the duration of a formed 
clot or decrease its resistance to fibrinolysis.  This led to investigations into the
hypofibrinolytic effects of CORM-2, which hypothesized that CORM-2 affects 
fibrinolysis either by promoting an inhibitory regulatory fibrinolytic protein, or by
inhibiting a fibrinolytic promoter.  A study was conducted studying the effects of 
CORM-2 on the inhibitory anti-fibrinolytic enzymes: Plasminogen Activating
Inhibitory-1 (PAI-1), Thrombin-Activable Fibrinolysis Inhibitor (TAFI), and α2­
antiplasmin.  This study concluded that clot formation and disintegration kinetics 
were more dependent on α2-antiplasmin activity than any other antifibrinolytic
7
 
    
   
  
     
    
  
   
  
  
  
 
 
  
 
 
 
 
  
 
 
  
 
enzyme tested (13). Deducing that α2-antiplasmin is the primary enzyme induced 
by CO to produce hypofibrinolysis, the next question to be answered is whether
α2-antiplasmin is modulated in a similar heme-dependent manner like fibrinogen, 
or by an entirely new mechanism.
The objective of the present study was to mechanistically assess CO and NO­
induced-heme-based modification of α2-antiplasmin mediated hypofibrinolysis.  It 
is hypothesized that CO-mediated modification of α2-antiplasmin may play a
major role in acquired hypofibrinolysis.
In order to determine the most efficient way of creating experiments to test the 
hypothesis, the following preliminary studies were performed:
α2-antiplasmin is CO-modulated enzyme
Purified α2-antiplasmin was exposed to 0 or 100μM CORM-2 and then diluted 
into α2-antiplasmin deficient plasma.  CORM-2 was diluted to 10-fold less than 
the concentrations associated with no detectable response, in order for there to be 
no fibrinogen-associated enhancement of clot growth or strength.  Purified α2­
antiplasmin exposed to CORM-2 resulted in a 42% increase in the time to 
maximum speed of lysis, a 31% decrease in the maximum speed of lysis, and a
39% prolongation in clot lysis time.  The results suggested that α2-antiplasmin is a 
CO-sensing molecule; further experiments were proposed to determine CO and/or 
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heme’s influence on α2-antiplasmin. The following preliminary studies were
performed to confirm α2-antiplasmin as a potential CO-sensing molecule.
1. Define CO and/or heme structural modification of α2-antiplasmin
It is known that α2-antiplasmin activity is enhanced by CO but the exact 
mechanism, possibly involving heme, remains to be identified.  It has been
discovered that CO modification independent of heme involved the K
+ 
channel Slo1­
BK (35).  Purified α2-antiplasmin was treated with 0-100μM CORM-2.  LC-MS
profile, post-proteolytic digestion, was used to identify regions of modification which 
change proteolytic enzymatic access such as direct modification by CO and/or 
presence of heme and/or altered proteolytic pattern. The results indicated heme 
binding is present, so experiments were reproduced using α2-antiplasmin to determine
how it uses heme to detect CO.  Histidines are established mediators of direct CO 
regulation of protein function (35).  If the experiments did not identify heme, 
histidines in recombinant α2-antiplasmin would have been mutated to both arginine
and alanine and tested for loss of CO responsiveness in order to determine site-
specific roles of CO enhancement of α2-antiplasmin activity (35). 
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2.	 Mechanistically assess CO-induced/heme-based modification of α2-
antiplasmin mediated hypofibrinolysis.
Using the structural knowledge gained during the first study, a
thrombelastographic-based coagulation/fibrinolysis assay array was created to 
identify CO-exposed, hypercoagulable plasma.  This procedure could be used as a 
diagnostic tool to determine the role CO-exposure has on tobacco smoke-associated 
hypercoagulability.  Normal plasma was obtained and subjected to 
thrombelastographic analyses to determine coagulation and fibrinolysis (13, 17-21).  
3.	 Heme Group Modulation Experiments
The following method was used to modulate heme binding and/or CO to 
mechanistically show the CO sensing mechanism in CO-mediated hypofibrinolysis.
Normal plasma and purified α2-antiplasmin were exposed to a NO donor in a cell
culture dish to competitively block CO access to heme (36, 37).  Plasma/proteins 
were exposed to 0-100μM CORM-2.  With fluid thickness kept to 1-2mm, CO was 
released from heme, and replaced by NO, thus allowing CO to be rapidly lost to the 
atmosphere.  The results determined that the CO-sensing mechanism of 
hypercoagulability is mediated through heme binding.
10
 
     
   
   
   
   
 
These preliminary studies provided insight into the CO-heme-α2-antiplasmin
interaction and its influence on fibrinolysis with or without exposure to CO.  The
preliminary studies provided guidance towards designing the experiments to test the
hypothesis that α2-antiplasmin is a heme-modulated-CO and NO-sensing molecule, in 
which CO-induced-heme-based-modification of α2-antiplasmin creates a
hypofibrinolytic system.
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Chapter 2: Materials and Methods
Plasma, enzymes and reagents
Pooled normal plasma (George King BioMedical, Overland Park, KS, 
USA) anticoagulated with sodium citrate was used for experimentation.  Plasma
deficient in α2-antiplasmin used in experimentation (Affinity Biologicals, Inc., 
Ancaster, Ontario, Canada) had a prothrombin time of 14.6 sec, an activated partial 
thromboplastin time of 33.4 sec, a fibrinogen concentration of 329 mg/dl and an α2­
antiplasmin activity of <1% of normal.  Purified α2-antiplasmin and plasmin (Enzyme
Research Laboratories, South Bend, IN, USA) were maintained at -80
o
C prior to 
experimentation.  Purified tissue factor (TF), dissolved in dH2O (Instrumentation
Laboratory, Lexington, MA, USA) and tissue plasminogen activator (tPA) at 580 
IU/μg (Genentech, Inc., San Francisco, CA, USA; 100 IU/ml final concentration) 
were maintained at 2-8
o
C prior to experimentation.  CORM-2, dimethyl sulfoxide 
(DMSO) and the oxidant O-phenylhydroxylamine (PHA, figure 4) were obtained 
from Sigma-Aldrich, St. Louis, MO, USA.  The nitric oxide (NO) donor used in 
experimentation was (Z)-1-[N-Methyl-N-[6-(N-methylammoniohexyl) amino]]
diazen-1-ium-1, 2-diolate (MAHMA NONOate, Cayman Chemicals, Ann Arbor, MI, 
USA, figure 5).
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Evaluation of MAHMA NONOate and PHA as antifibrinolytic agents in
pooled normal plasma
In a similar matter as the heme-mediated modulation of fibrinogen (28), 
conversion of the putative α2-antiplasmin associated heme to a metheme (see Table 1)
with nitric oxide (NO) or a well characterized, rapid heme-specific organic oxidant 
was attempted.  The nitric oxide donor, MAHMA NONOate, has a half-life of 2.7 
min at 22
o
C at pH 7.4 and releases 2 moles of NO per mole of donor molecule.  
MAHMA NONOate is stable for 24h after suspension in 0.01M NaOH.  PHA was 
chosen for this study as it is the most rapid and effective metheme forming oxidant 
known (38) and effectively converts fibrinogen-bound heme to a metheme state
(unpublished data).  PHA was dissolved in dH2O on the day of experimentation.  The
sample composition (sequentially added in this order) consisted of 316 μl of plasma; 
10 μl of TF (0.1% final concentration), 10 μl tPA (final activity 100 U/ml), either 3.6 
μl of MAHMA NONOate (final concentration 0, 1 or 2mM) or PHA (final
concentration 0, 5 or 10 mM), and 20 μl of 200 mM CaCl2, for a final volume for this 
experimental series of 359.6μl. Eight replicate experiments were performed per 
condition tested.
Plasma sample mixtures were placed in a disposable cup in a computer-
controlled thrombelastograph
® 
hemostasis system (Model 5000, Haemoscope Corp., 
Niles, IL, USA), with addition of CaCl2 as the last step to initiate clotting.  Data were
collected until clot lysis time occurred.  The following variables were determined at 
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37
o
C: clot growth time (CGT, time from clot amplitude of 2mm [102 dynes/cm
2
] 
until maximum strength is achieved, in min), clot lysis time (CLT, time from when 
maximum strength was observed to 2mm amplitude, in min) and clot lifespan (CLS, 
the sum of CGT and CLT).  The nomenclature used to describe these phenomena is as 
follows: Time to maximum rate of thrombus generation (TMRTG): The time 
interval (min) observed prior to maximum speed of clot growth.  Maximum rate of
thrombus generation (MRTG): The maximum velocity of clot growth observed 
(dynes/cm
2
/sec).  Total Thrombus Generation (TTG): The total area under the
velocity curve clot growth (dynes/cm
2
), representing the amount of clot strength 
generated during clot growth.  Time to maximum rate of lysis (TMRL): The time 
interval (min) measured from the time of maximum strength to the time when the 
velocity of clot disintegration is maximal.  Maximum Rate of Lysis (MRL): The
maximum velocity of clot disintegration observed (-dynes/cm
2
/sec).  Area of Clot
Lysis (ACL): The total area under the velocity curve during clot disintegration.  As 
this model involves complete fibrinolysis, TTG is equivalent to ACL, so ACL was 
not presented as it provides no additional information. For a graphical representation 
of the Clot Lifespan Model, refer to figure 6.
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Isolated exposure of α2-antiplasmin to MAHMA NONOate and PHA
Purified α2-antiplasmin (154 μg per condition) was diluted into 5% human 
albumin (CSL Behring LLC, Kankakee, IL, USA), to a concentration of 50 μg /ml, 
and suspended in Isolyte
® 
a calcium-free electrolyte solution with pH 7.4 (B. Braun 
Medical Inc., Irvine, CA, USA).  Each aliquot of diluted α2-antiplasmin was exposed
to 1% by volume of one of the following: DMSO, MAHMA NONOate (final 
concentration 2mM), PHA (final concentration 5mM) or CORM-2 (final 
concentration 100 μM). Solutions were incubated at 37oC for 5 min and then left at 
room temperature during experimentation.  The sample composition consisted of 288 
μl of α2-antiplasmin deficient plasma; 32 μl of exposed, diluted, purified α2­
antiplasmin (50 μg/ml final activity); 10 μl of TF (0.1% final concentration), 10μl 
tPA (final activity 100 U/ml), and 20 μl of 200 mM CaCl2 for a final volume for this 
experimental series of 360 μl. Plasma sample mixtures were placed in a disposable 
cup in a computer-controlled thrombelastograph
®
.  Data were collected until clot lysis
time occurred.  Six replicate experiments were performed per condition tested.
15
 
  
 
 
 
  
 
 
 
     
 
 
 
 
 
 
  
 
Spectrophotometric antiplasmin activity assay
A commercially available plasmin inhibitor kit (diaPharma Group, 
Inc., West Chester, OH, USA) was utilized.  This kit allows spectrophotometric 
assessment of the ability of plasmin to cleave an artificial substrate with subsequent 
release of p-nitroaniline which is measured at 405 nm.  Pooled, normal, platelet poor 
plasma (George King Bio-Medical) anticoagulated with sodium citrate was utilized 
for experimentation.  Plasma was serially diluted to generate a standard curve with a 
range of 0-124% of normal as per the manufacturer’s instructions.  Additional plasma 
samples diluted 50% with the buffer provided in the kit were exposed to 2 mM 
MAHMA NONOate or 2 mM PHA, and eight replicate reactions for each condition 
were recorded. Results with a greater than 124% normal activity represent inhibition 
beyond the range of the standard curve.
Isolated exposure of plasmin to MAHMA NONOate and CORM-2
Purified plasmin was suspended into 5% human albumin/Isolyte
® 
and exposed
to 1% volume of either 0.01 M NaOH, MAHMA NONOate (final concentration 2 
mM) or CORM-2 (final concentration 100 μM). Plasmin solutions were incubated at 
37
o
C for 5 min and then left at room temperature during experimentation.  The final 
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volume for this experimental series was 350 μl.  The sample composition consisted, 
in this order, of 297 μl of pooled normal plasma; 33 μl of 5% human albumin/Isolyte® 
with or without vehicle/NO/CO, purified plasmin (30 μg/ml final activity); 10 μl of 
TF (0.1% final concentration), and 20μl of 200 mM CaCl2. Plasma sample mixtures 
were placed in a disposable cup in a computer-controlled thrombelastograph
®
. Data 
were collected for 15 min.  Eight replicate experiments per condition were performed.
LC-MS/MS detection of heme associated with α2-antiplasmin and plasmin
Stock solution of α2-antiplasmin (50 μg /ml) and plasmin (209 μg /ml) or 50 
μg of BSA (Sigma-Aldrich) were digested in 50 mM ammonium bicarbonate buffer, 
pH 8.0, using sequence grade modified trypsin (Promega, Madison, WI, USA).  Prior
to digest, samples were reduced by 10 mM dithiothreitol (Sigma-Aldrich) for 1 hour 
at room temperature, and alkylated by 50 mM iodoacetamid (Sigma-Aldrich) for 1 
hour at room temperature in the dark.  Acidified digests (<pH 4) were desalted with 
reverse phase C18 Zip-Tips (Millipore, Billerica, MA, USA), dried, and re-suspended 
in 0.1% trifluoroacetic acid (TFA).
LC-MS/MS runs were completed using an Eksigent Nano LC-AS1 auto-
sampler (Eksigent, Dublin, CA, USA) coupled with an LTQ linear ion trap mass 
spectrophotometer (Thermo Fisher Scientific, San Jose, CA, USA).  Samples were
injected onto an Integra Frit Proteopep II (New Objective, Wobum, MA, USA) C18 
17
 
  
   
   
 
  
 
 
 
 
 
 
 
 
 
 
sample trap column (300 Å x 75 μm internal diameter x 2.5 cm bed length) at flow 
rate of 3 μl/min (0.1% TFA) for 15 minutes.  The inline capillary column for reverse
phase was an Integra Frit Proteopep II (New Objective) C18 column (300 Å x 75 μm 
internal diameter x 10 cm bed length).  Sample was eluted from the trap column by a
35 min 2-38% linear gradient of buffer B (100% acentonitrile.1% TFA), followed by
an 8 min 38-90% linear gradient of buffer B to a 10 min isocratic elution of 90% of 
buffer B at a flow rate of 300 nL/min.  Collision energy of collision-induced 
dissociation was 35.0, and data acquisition was performed using a full MS scan, a
zoom scan for the most intense ion, and MS/MS fragmentation.  Centroid data was 
acquired except in case of zoom scan, where profile data was acquired.  The
electrospray voltage was 1.6 kV, positive polarity.  The mass range for MS scans was 
400-2,000 Da.  Data was acquired using an isolation width of 2 m/z and activation 
time of 30 ms for MS and MS/MS scan types.  Dynamic exclusion was set such that if 
an ion was chosen for MS/MS twice, it would be ignored for 45 seconds.  Sequence
data analysis to identify peptides and proteins was performed using Sequest in 
Bioworks (Thermo Fisher Scientific) software.  Both a non-redundant FAST-ALL
(FASTA) human database and a custom made sub-database for human α2-antiplasmin 
and plasmin were interrogated.  A cross-correlation (X-Cor) score of 2.5 or better for
doubly charged and 3 for triply charged precursors were set as threshold for 
identifications.  BSA digests were also analyzed to control for enzyme digest and 
mass spectrometer identification consistency.  All peptides of interest were analyzed 
manually via MS/MS spectra.
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After adequate identification of each enzyme, samples were queried to 
determine if heme was present in α2-antiplasmin and plasmin with BSA as a negative
control.  Heme has a molecular weight of 616.18 in the reduced Fe
+2 
state.  During
mass spectrometry, heme binding proteins are known to liberate free heme (39) which
can be detected at m/z 617.18 in the
+1 
charge state (34, 39).
Statistical Analyses
Thrombelastographic data are presented as either median and 1
st
-3
rd 
quartiles 
or mean ±SD as appropriate following analysis of normality and variance.  Analyses 
of the effects of MAHMA NONOate and PHA thrombelastographic parameter values 
in normal pooled plasma were conducted with Kruskal-Wallis one way analysis of 
variance (ANOVA) with the Student-Newman-Keuls post hoc test (SigmaStat 3.1, 
Systat Software, Inc., San Jose, CA, USA).  Analyses of the effects of MAHMA
NONOate or PHA on α2-antiplasmin were conducted with one way ANOVA with the 
Holm-Sidak post hoc test. A separate, confirmatory analysis of the effects of CORM­
2 on isolated, purified α2-antiplasmin was performed with an unpaired Student’s t-
test. Analyses of the effects of MAHMA NONOate and CORM-2 on plasmin activity
were conducted with one way ANOVA with the Holm-Sidak post hoc test. Graphical 
representation of the data was generated with commercially available software (origin 
7.5, OriginLab Corp., Northampton, MA, USA; and, CorelDRAW 12.0, Corel 
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Corporation, Ottawa, Ontario, Canada).  A P value of <0.05 was considered
significant.
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Chapter 3: Results
Evaluation of MAHMA NONOate and PHA as antifibrinolytic agents in
pooled normal plasma
MAHMA NONOate and PHA’s antifibrinolytic effects on normal, pooled 
plasma are displayed in tables 2 and 3.  In samples exposed to 1 mM MAHMA
NONOate, there was a small but significant attenuation in coagulation kinetics, with a
mild profibrinolytic effect seen by a decrease in TMRL.  However at a concentration 
of 2 mM, coagulation kinetics were normal, with clear antifibrinolytic effect 
represented by significant increases in TMRL, CGT, CLT, and CLS.  PHA at a 10 
mM concentration had a significant attenuation in coagulation kinetics, consistent 
with the formation of methemefibrinogen as previously reported with organic 
oxidants and unpublished, ongoing investigation (28).  There was a smaller
antifibrinolytic effect with PHA, with a significant decrease in MRL at 5 and 10 mM
concentrations, and only a significant prolongation of CGT at 10 mM.
21
 
  
 
 
 
 
   
  
 
 
 
  
 
  
 
 
 
Isolated exposure of α2-antiplasmin to MAHMA NONOate, PHA and
CORM-2
α2-antiplasmin was exposed to MAHMA NONOate and PHA; the effects on 
fibrinolysis are displayed in table 4.  MAHMA NONOate and PHA significantly
decreased TMRL, and shortened CLT and CLS.  Additionally, MAHMA NONOate 
significantly increased MRL.  These substantial profibrinolytic effects of the two 
compounds after exposure of isolated α2-antiplasmin are opposite of that observed in 
normal plasma (tables 2 and 3).  To rule out that this contradictory result was possibly
due to using a different source of α2-antiplasmin, as previously reported (28), we
compared unexposed purified α2-antiplasmin with α2-antiplasmin exposed to CORM­
2. Comparable to our lab’s previous report [38], CORM-2 significantly increased 
MRTG (4.8±0.5 dynes/cm
2
/sec), increased TTG (121±10 dynes/cm
2
), increased 
TMRL (11.5±3.7 min), decreased MRL (-0.7±0.1 dynes/cm
2
/sec), increased CLT 
(22.4±2.0 min) and increased CLS (26.3±2.2 min).  Overall, NO or PHA mediated 
conversion of a putative heme to metheme state associated with α2-antiplasmin results 
in increased fibrinolysis, whereas a carboxyheme state decreases fibrinolysis.  The 
thrombus growth/disintegration curves representative of this data is presented in 
figure 7.
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Spectrophotometric antiplasmin activity assay
Normal plasma diluted by 50% that was exposed to PHA had a 76.8±5.3% α2­
antiplasmin activity, whereas plasma exposed to MAHMA NONOate resulted in 8 
replicates with >124% normal activity (inhibition beyond the range of the standard 
curve).
Isolated exposure of plasmin to MAHMA NONOate and CORM-2
MAHMA NONOate and PHA decreased α2-antiplasmin activity in isolation. 
While both compounds appeared to enhance overall inhibition of plasmin activity in 
the spectrophotometric-based experiments, the possibility that plasmin was directly
inhibited by either NO or CO was investigated.  A previous study demonstrated that 
unlike tPA, plasmin addition did not result in delayed fibrinolysis but instead 
decreased MRTG and TTG (40).  This demonstrated in a thrombelastographic model 
that plasmin, a non-propagating fibrinolytic agent, could have changes in its activity
determined by changes in thrombus velocity of growth and final strength (40).  NO 
and CO’s effects on plasmin activity are depicted in table 5.  Plasmin significantly
decreased MRTG and TTG, whereas exposure of plasmin to either MAHMA 
NONOate or CORM-2 significantly attenuated the plasmin mediated decrease in 
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coagulation kinetics to similar extents.  In sum, both NO and CO decreased plasmin 
activity.  Thrombus formation curves representative of these data are presented in 
figure 8.
LC-MS/MS detection of heme associated with α2-antiplasmin and
plasmin
We were unable after two attempts to recover more than 10% of α2­
antiplasmin’s amino acid sequence, likely secondary to extensive glycosylation (34).  
It is our expectation that ongoing work to deglycosylate and adequately
proteolytically digest α2-antiplasmin will result in identification of an α2-antiplasmin 
associated heme.  In the case of plasmin, approximately 70% of the enzyme’s amino 
acid sequence could be identified following digestion with trypsin.  Regarding the 
pursuit of the presence of a heme group released from plasmin, an ion with an 
approximate m/z of 617.15 similar to the characteristic m/z 617.18 [M+H]
1+ 
heme ion 
was detected as base peak from the acetonitrile gradient at the appropriate elusion 
time of 62.22 minutes (34, 39) in plasmin samples but was not found in BSA samples 
(negative control).  A typical example of such spectral data is displayed in figure 9.
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Chapter 4: Conclusion
The effects of α2-antiplasmin and plasmin were diminished by NO or PHA;
however α2-antiplasmin’s antifibrinolytic effects remained more dominant indicating
that plasmin’s activity is the crucial biochemical event in this process.  The
importance of this study is to show that, when plasma is exposed to NO or a heme-
binding oxidant, the hypofibrinolytic effects exhibited are most likely secondary to 
inhibition of plasmin or by α2-antiplasmin enhanced by conversion of an attached 
heme to a metheme state. This builds on our lab’s previous investigations 
demonstrating that CO-influenced antifibrinolytic effects are due to both the 
augmentation of α2-antiplasmin and inhibition of plasmin activity (13, 28). The
molecular mechanism responsible for inhibition of plasmin activity by NO or CO is 
most likely conversion of the associated heme to either a metheme or carboxyheme
state, respectively.  It is also likely that the up/down regulation of α2-antiplasmin 
activity by CO or NO involves an associated heme, as in the case of the enhancement 
of fibrinogen as a substrate by CO (34).  In summary, the effects of CO and NO on 
the fibrinolytic/antifibrinolytic system are complex, involve α2-antiplasmin-plasmin 
interactions, and are likely mediated by attached heme groups.  
Given the novelty of the proposed idea that diatomic gases modulate heme
groups attached to fibrinogen, α2-antiplasmin, and plasmin causing changes in
coagulation and fibrinolysis, skepticism can be expected.  Hemoglobin, myoglobin, 
peroxidases and porphyrins are just some of the biological proteins and enzymes 
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known to contain a heme functional group.  Hemoproteins have diverse biological 
functions including the transport of diatomic gases, chemical catalysis, diatomic gas 
detection, and electron transfer.  Heme groups reacting with diatomic gases such as 
O2, NO, and CO resulting in modulation of the substrate and/or signal transduction 
(enhancement/inhibition) of the substrate has been thoroughly investigated and is a
widely accepted concept (41).  It is well know that iron in the Fe
2+ 
state is available to 
bind diatomic gases, whereas iron in the Fe
3+ 
is unable to bind with diatomic gases 
(41-44).  Lastly, gas sensing molecules containing heme groups have been shown to 
have distinct affinities for specific diatomic gases, while at the same time having no 
affinity to others. So while there may be skepticism towards this new phenomenon, 
there are many accepted biochemical principles which together provide evidence to 
support the hypothesis.  
In our experiments, 4000 μM NO was required to modulate α2-antiplasmin or 
plasmin, as compared to only 75 μM CO (NO:CO molar ratio 53:1).  NO and CO are
both components of cigarette smoke, albeit in different amounts (45).  Combustion of 
a single cigarette releases approximately 0.2 mg of NO (30 Da) and 12 mg of CO (28 
Da), with a NO:CO molar ratio of 1:64 (45).  If only 50% of expected CO derived 
from combustion of two cigarettes (12 mg) were dissolved into the plasma volume of 
a 70 kg subject (approximately 3 L), then the consequent CO concentration would be
more than 140 μM – an amount that meets/exceeds the 75-150 μM CO required to 
effect maximum hypofibrinolysis in vitro in plasma (13). Therefore it would be 
expected that cigarette smoke exposure would essentially guarantee the 
hypofibrinolytic state reported after smoking two cigarettes (29).Taken as a whole, 
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our present and previous in vitro results mechanistically account for the majority of 
procoagulant/hypofibrinolytic responses to smoking, given the gas mixture resulting
from the combustion of cigarettes (28, 33, 34, 46).
Even though tobacco smoke produces a hypercoagulable state, it has also been 
shown that CORM-released CO inhibits platelet aggregation in vitro in both humans 
and rats (47, 48).  However, it should be observed that human (47) and rat (48)
platelet aggregation is decreased approximately 17% and 35%, respectively, by 75 
μM CO.  Further, the bleeding time of a rat tail-tip amputation model (48) was 
increased by only 30% following a 30 mg/kg administration of CORM-3 
(tricarbonyldichloro (glycinato) ruthenium (II); 295 Da) – this concentration of
CORM-3 would be expected to release >1400 μM CO.  CO released at this 
concentration would be 10 times greater than the concentration required to maximally
enhance coagulation and attenuate fibrinolysis in vitro (13) following exposure of 
plasma to CORM-2 or released after smoking two cigarettes (46). In addition, the 
30% prolongation of bleeding time in response to such a large administration of CO is 
far less significant than the 300% increase in bleeding time after administration of
Clopidogrel (see Table 1) in the same animal model (48).  So, even though the 
antiplatelet effects of CO have been well-documented (47, 48), clinically it has been 
demonstrated that the encountered concentrations of CO elicit protein-mediated 
hypercoagulability, without discernable loss of (indeed, enhancement of) platelet 
activity following exposure to tobacco smoke (33).
There are still many important issues to be determined; the duration of CO 
mediated hypercoagulability in vivo is undetermined, as well as the extent of CO 
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influence on smoking-associated perioperative thrombophilia (49, 50).  Currently, 
CO-mediated hypercoagulability and hypofibrinolysis is being examined in rabbit 
models, in order to evaluate the coagulant effects of CO in vivo, and to determine
dose efficacy. Future studies involving CORM-2  may include: evaluating the plasma
of smokers and the effect CO has on the coagulation kinetics of their plasma, case
studies on the intra-operative course of patients with a history of smoking (how a
chronically increased COHb concentration may increase the risk of thrombotic events 
intra/post-operatively), and ultimately designing a diagnostic tool to assist in 
identifying patients at risk of spontaneous thrombotic events, or other events 
associated with trauma, surgery, smoke inhalation etc. CORM-2-mediated-release of 
CO should also be evaluated as a possible therapeutic procoagulant treatment or as an 
adjuvant to currently used procoagulants such as recombinant activator human factor 
VII, fresh frozen plasma, thrombin/fibrin glue, and zeolites.
In conclusion, the effects of α2-antiplasmin and plasmin are modulated by CO and 
NO.  This likely due to the secondary conversion of an attached heme group(s) to 
carboxyheme and metheme states, respectively.  Given the known amount of CO in 
cigarettes (46) and the positive correlation between chronic smoking and a
procoagulant state (33, 51-55), this study supports the hypothesis that CO modulation 
of fibrinogen (34), α2-antiplasmin (28) and plasmin play a critical role in tobacco-
associated thrombophilia (56).
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Figure 1. The Coagulation and Fibrinolytic Cascades
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Figure 2.  Chemical Structure of CORM-2 Molecule
Figure 3. Structure of α2-antiplasmin
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Figure 4. Chemical Structure of Phenylhydroxylamine
Figure 5. Chemical Structure of (Z)-1-[N-Methyl-N-[6-(N-methylammoniohexyl) 
amino]] diazen-1-ium-1, 2-diolate (MAHMA NONOate)
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Figure 7.  Effects of NO and CO on isolated, purified α2-antiplasmin activity
Panel A: Fifty μg/ml of α2-antiplasmin was added to α2-antiplasmin deficient plasma 
in the presence of tPA.  Panel B:  NO derived from MAHMA NONOate was added to 
α2-antiplasmin prior to reaction, accelerating fibrinolysis.  Panel C:  CO derived from 
CORM-2 was added to α2-antiplasmin prior to reaction, attenuating fibrinolysis.
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Figure 8.  Effects of NO on isolated, purified plasmin activity
Coagulation in normal plasma (black trace) was inhibited by addition of plasmin 
(light gray trace).  Plasmin exposed to NO derived from MAHMA NONOate (gray
trace) decreased coagulation to a significantly lesser extent than unexposed plasmin.
40
 
    
 
 
 
   
 
    
    
 
Figure 9.  Evidence of free heme in tryptic digest of human plasmin.
Panel A: A reverse phase LC-MS/MS analysis of a tryptic digest of human purified 
plasmin; the full MS scan reveals a m/z 617.15, corresponding to singly charged 
reduced heme. Panel B: An extracted ion chromatogram of m/z 617.15 reveals the
heme elution time of 62.22 minutes during LC-MS/MS. 
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Appendix B
 
List of Tables
 
Table 1.  Abbreviations and Definitions
Terms Explanation/Example
α2 -antiplasmin A serine protease responsible for inactivating
plasmin, inhibiting fibrinolysis
Argatroban An anticoagulant which is a direct thrombin 
inhibitor, often used to treat thrombosis in 
patients with heparin-induced 
thrombocytopenia (HIT)
Carboxyhemoglobin (COHb) A stable complex of carbon monoxide and the 
hemoglobin of red blood cells which forms 
due to the inhalation of carbon monoxide or
by normal metabolism
Clopidogrel An antiplatelet agent that irreversibly inhibits 
the P2Y12 subtype of the ADP receptor; is 
important in the aggregation of platelets and 
cross-linking fibrin
Fibrin The active form of fibrinogen which 
polymerizes to form a mesh which becomes a
hemostatic plug or clot over a wound site
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Fibrinolysis The process of breaking down a fibrin clot;
plasmin is the primary enzyme responsible for 
dissolving fibrin clots
Heme A prosthetic group consisting of iron at the
center of a large heterocyclic ring known as a 
porphyrin; among many biochemical 
functions, hemes transport diatomic gases 
(such as CO, NO, and O2) when the iron is in 
the Fe
2+ 
state, when chemicals such as PHA
react with heme, it converts Fe
2+  Fe3+ ,
inhibiting the ability of heme to freely bind 
diatomic gases
Heparin A faster acting anticoagulant than Warfarin, it
works by activating antithrombin III which 
inactivates thrombin
Liquid Chromatography (LC) A laboratory technique using a machine to 
separate a mixture, so as to purify it or 
identify its contents
MAHMA NONOate A chemical compound used as a nitric oxide 
(NO) donor for these experiments, in a
phosphate buffer at pH 7.4, the T1/2~3.5 
minutes
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Mass Spectrometry (MS) A laboratory technique using a machine to 
determine the mass-to-charge ratio of charged 
particles in order to determine the elemental 
composition of a sample or molecule
Methemoglobin (metheme) A form of hemoglobin in which the iron of the 
heme group is in the Fe
3+ 
state, inhibiting its 
ability to bind diatomic gases such as O2 or
CO
Phenylhydroxylamine (PHA) An organic compound used as an oxidant in 
these experiments to convert the iron on heme 
molecules from a Fe
2+ Fe3+ state
Plasmin The enzyme responsible for dissolving fibrin 
clots; it is converted from plasminogen to the
active form plasmin by tPA
Protamine A drug which reverses heparin by binding and 
inhibiting it
Recombinant Activating Factor VII
(RAF VII)
Manufactured FVII used for initiating
coagulation during uncontrollable
hemorrhage, i.e. hemophilia patients
Thrombelastography (TEG) A method of testing the efficiency of 
coagulation. A sample of blood or plasma is 
placed in a small cup and gently rotated to 
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imitate sluggish venous flow to activate 
coagulation.  A small pin sensor is placed into 
the cup and a clot forms between the pin and 
the cup.  Parameters such as clot speed and
strength are measured during this process
Thrombin An enzyme whose major role is to convert 
fibrinogen to fibrin, initiating the formation of
a hemostatic plug (clot)
Tissue Factor (TF) The cell surface receptor for the serine
protease Factor VIIa, which activates Factor 
X, the first step of the common coagulation 
pathway; TF is an activator of the extrinsic
pathway
Tissue-type Plasminogen Activator An enzyme that catalyzes the formation of 
(tPA) active plasmin from its inactive form 
plasminogen; plasmin is the major enzyme 
responsible for fibrinolysis
Warfarin A slower acting anticoagulant used for
patients requiring chronic anticoagulation; it 
acts by inhibiting vitamin K-dependent 
synthesis of calcium-dependent clotting
factors II, VII, IX, X and proteins C, S, and Z
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Table 2.  Effects of MAHMA NONOate on tPA mediated fibrinolysis in normal, 
pooled plasma.
Condition of 
MAHMA
NONOate
0 mM 1 mM 2 mM
C
o
a
g
u
la
n
t 
TMRTG 2.5(2.5, 2.6) 3.1(3.0, 3.2)* 2.7(2.5, 2.7)*†
MRTG 5.8(5.2, 6.3) 4.4(4.1, 4.8)* 6.0(5.6, 6.5) †
TTG 120(107,127) 94(86,101)* 118(109,131) †
CGT 3.1(2.6, 3.4) 2.7(2.6, 2.9) 3.8(3.2, 4.5)*†
F
ib
ri
n
o
ly
ti
c 
TMRL 7.9(6.6, 9.4) 6.2(4.3, 6.9)* 13.4(9.2, 15.0)*†
MRL -1.1(-1.2,-1.0) -1.2(-1.3,-1.0) -1.2(-1.3,-1.0)
CLT 13.0(12.6, 13.6) 11.3(9.7, 13.4) 18.2(16.0, 23.0)*†
C
G
T
+
C
L
T
CLS 16.2(15.56, 17.0) 14.2(12.1, 16.2) 22.6(19.1, 26.6)*†
Data are presented as median (1
st
-3
rd 
quartiles). TMRTG = time to maximum 
rate of thrombus generation (min); MRTG = maximum rate of thrombus generation 
(dynes/cm
2
/sec); TTG = total thrombus generation (dynes/cm
2
); TMRL = time to 
maximum rate of lysis (sec); MRL = maximum rate of lysis (-dynes/cm
2
/sec); CGT =
clot growth time (min); CLT = clot lysis time (min); CLS = clot lifespan (min).  
*P<0.05 vs. 0 mM PHA, †P<0.05 vs. 1 mM MAHMA NONOate.
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Table 3.  Effects of PHA on tPA mediated fibrinolysis in normal, pooled plasma.
Condition of 
PHA
0 mM 5 mM 10mM
C
o
a
g
u
la
n
t 
TMRTG 3.0(2.2, 3.2) 2.9(2.9, 3.0) 3.6(3.5, 3.8)*†
MRTG 5.0(4.4, 6.5) 4.2(4.0, 4.7) 3.5(3.2, 3.8)*†
TTG 113(101,119) 96(90,102) 89(80, 96)*†
CGT 3.0(2.6, 3.6) 3.8(2.9, 4.2) 5.0(4.2, 5.2)*†
F
ib
ri
n
o
ly
ti
c 
TMRL 7.5(5.0, 9.4) 6.9(6.1, 11.3) 9.7(6.6, 11.4)
MRL -0.9(-1.1,-0.8) -0.7(-0.9,-0.6)* -0.7(-0.8,-0.7)*
CLT 14.6(12.5, 15.0)
16.7(12.5, 
20.9)
17.9(14.2, 
18.4)
C
G
T
+
C
L
T
CLS 17.4(15.4, 18.9)
20.0(15.8, 
25.0)
21.8(19.4, 
23.6)
Data are presented as median (1
st
-3
rd 
quartiles). TMRTG = time to maximum 
rate of thrombus generation (min); MRTG = maximum rate of thrombus generation 
(dynes/cm
2
/sec); TTG = total thrombus generation (dynes/cm
2
); TMRL = time to 
maximum rate of lysis (sec); MRL = maximum rate of lysis (-dynes/cm
2
/sec); CGT =
clot growth time (min); CLT = clot lysis time (min); CLS = clot lifespan (min).  
*P<0.05 vs. 0 mM PHA, †P<0.05 vs. 5 mM PHA.
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Table 4. Effects of exposure of purified α2-antiplasmin to MAHMA NONOate
or PHA on tPA mediated fibrinolysis in α2-antiplasmin deficient plasma.
Condition No Exposure
MAHMA
NONOate 
(2mM)
PHA
(5mM)
C
o
a
g
u
la
n
t
TMRTG 4.0±0.2 3.6±0.1* 3.6±0.2*
MRTG 4.1±0.6 4.8±0.4 4.5±0.5
TTG 100±10 108±6 102±11
CGT 3.4±0.6 3.4±0.7 3.1±0.6
F
ib
ri
n
o
ly
ti
c TMRL 7.5±2.5 4.4±0.8* 4.8±0.8*
MRL -0.9±0.2 -1.8±0.3* -1.1±0.2†
CLT 13.8±2.3 7.7±0.9* 11.0±1.9*†
C
G
T
 +
 C
L
T
CLS 17.1±2.2 11.1±1.4* 14.2±2.1*†
No Exposure = α2-antiplasmin not exposed to MAHMA NONOate or PHA; 
MAHMA NONOate = α2-antiplasmin exposed to 2 mM MAHMA NONOate; PHA =
α2-antiplasmin exposed to 5 mM PHA. Data are presented as mean±SD. TMRTG =
time to maximum rate of thrombus generation (min); MRTG = maximum rate of
thrombus generation (dynes/cm
2
/sec); TTG = total thrombus generation (dynes/cm
2
); 
TMRL = time to maximum rate of lysis (sec); MRL = maximum rate of lysis (­
dynes/cm
2
/sec); CGT = clot growth time (min); CLT = clot lysis time (min); CLS =
clot lifespan (min). *P<0.05 vs. no exposure, †P<0.05 vs. MAHMA NONOate
exposure.
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Table 5.  Effects of MAHMA NONOate and CORM-2 on plasmin-mediated
decreases in coagulation in normal, pooled plasma.
Condition
No 
Plasmin
Plasmin
MAHMA
NONOate
CORM-2
C
o
a
g
u
la
n
t 
TMRTG 2.2±0.1 2.0±0.1* 2.0±0.1* 2.0±0.1*
MRTG 6.5±0.4 3.7±0.4* 5.7±0.6*† 4.9±0.5*†‡
TTG 138±7 90±6* 116±10*† 111±11*†
No Plasmin = no addition of plasmin; Plasmin = 50 μg/ml plasmin addition;
MAHMA NONOate = addition of plasmin exposed to 2 mM MAHMA NONOate;
CORM-2 = addition of plasmin exposed to 100 μM CORM-2. Data are presented as
mean±SD.  TMRTG = time to maximum rate of thrombus generation (min); MRTG =
maximum rate of thrombus generation (dynes/cm
2
/sec); TTG = total thrombus 
generation (dynes/cm
2). *P<0.05 vs. no plasmin, †P<0.05 vs. plasmin, ‡ vs. plasmin
exposed to MAHMA NONOate.
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Table 6. Overview of Molecules with Hemes and Effects
Molecules CO NO PHA
Normal Pooled Plasma
Enhances 
Coagulation,
Inhibits of
Fibrinolysis
Decreases 
Coagulation;
prolongs onset 
of fibrinolysis
Decreases 
Coagulation;
decreases rate
of fibrinolysis
Fibrinogen
Enhances 
velocity of clot 
growth and
strength
Decreases 
velocity of clot 
growth and
strength
Decreases 
velocity of clot 
growth and
strength
α2 -antiplasmin
Enhances 
enzyme activity, 
producing a
carboxyheme
state, and
antifibrinolytic 
effects
Inhibits activity, 
producing a
metheme state
and 
profibrinolytic 
effects
Inhibits activity, 
producing a
metheme state, 
and 
profibrinolytic 
effects
Plasmin Inhibition Inhibition Inhibition
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